Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
Emerging research suggests that magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) may be a viable option for the treatment of patients with localized prostate cancer.
For the prospective study, which was recently presented at the 2023 Society of Urologic Oncology (SUO) Annual Meeting, researchers assessed the use of MRI-guided TULSA in 126 patients (median age of 68) with localized prostate cancer based on data from follow-up prostate MRI and biopsy at one year and prostate-specific antigen (PSA) testing every three months. The median baseline PSA was 6.2 ng/mL and the baseline median prostate volume was 44 mL, according to the study.1
(Editor’s note: This article has been adapted from its original publication in our sister publication Urology Times.)
At 1 year after MRI-guided TULSA, PSA levels across the cohort had decreased by 72.1 percent.
Half of the study population (63/126 patients) had received a 1-year follow-up MRI at the time of the analysis. The 1-year imaging results in these patients showed that prostate volume had decreased by 51.4 percent and median PSA density had decreased by 49.9 percent.
“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” wrote lead study author Emily Bochner, M.D., a urology resident at UT Southwestern Medical Center, and colleagues.
The 1-year MRI results also showed that 28.6 percent (18/63) of these patients had “concerning” focal lesions. The location of 12 of these lesions was in field compared to the TULSA ablation area, and the other six lesions were out of field. Subsequent biopsy showed that 44 percent of the concerning lesions detected on MRI were positive for prostate cancer, according to the researchers.
Over a third (36.5 percent) of patients (23/63) who received a 1-year MRI had negative imaging results and subsequently refused to receive a 1-year biopsy. The other 40 patients (63.5 percent) who had received a 1-year MRI “underwent repeat systemic plus targeted (when applicable) biopsy at 1 year,” noted Bochner and colleagues on their poster.
The biopsy results for these 40 patients showed that 26 (65 percent) of these patients were negative for recurrence while 14 (35 percent) of these patients had prostate cancer recurrence. The tumors were Gleason grade (GG) 1 for four of these patients, GG2 for six patients, and GG3 for one patient. The tumors for three of the patients were ungraded due to treatment effect, according to the study investigators.
(Editor’s note: For additional related content on prostate cancer imaging, click here.)
Of the 14 patients with recurrence, 10 (71 percent) were managed with active surveillance and four (29 percent) received salvage treatment. The salvage treatments consisted of surgery, radiation, or repeat TULSA.
Emphasizing that salvage treatment was only required in four out of 63 patients with one-year follow-up data, Bochner and colleagues et al concluded that salvage treatment being required by only 4 (6%) of 63 patients with 1 year of follow-up shows “promising primary treatment efficacy at this early time point in our TULSA experience.”
Reference
1. Bochner E, Balcazar J, Recchimuzzi, et al. MRI guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: single institution experience of treatment efficacy. Presented at: 2023 Society of Urologic Oncology Annual Meeting. November 28 – December 1, 2023; Washington, DC. Abstract 188.
Prostate MRI Study Examines Key Predictors of False-Negative and False-Positive Results
February 17th 2025Researchers found that patients with high PSA density have more than double the risk of false-negative findings on prostate MRI and those with low PSA density are significantly less likely to have false-positive results.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
Can MRI-Based Deep Learning Improve Risk Stratification in PI-RADS 3 Cases?
January 30th 2025In external validation testing, a deep learning model demonstrated an average AUC of 87.6 percent for detecting clinically significant prostate cancer (csPCA) on prostate MRI for patients with PI-RADS 3 assessments.
